Disease details

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

5 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2015-003147-19-GR (EUCTR)	18/07/2016	25/05/2016	To confirm the safety and efficacy of NEUROASPIS PLP10® in the treatment of individuals, who have been diagnosed with relapsing remitting multiple sclerosis (MS).	Novel Oral Nutraceutical Intervention NEUROASPIS PLP10® for the Treatment of Relapsing-Remitting Multiple Sclerosis: A Multicenter, Parallel-group, Phase III, Double-blind, Randomized, Placebo-Controlled, Add-on with Interferon Beta, Trial of Efficacy and Safety. - Efficacy and Safety study of NEUROASPIS PLP10® versus placebo	Relapsing-Remitting Multiple Sclerosis (RRMS) MedDRA version: 19.0;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: NEUROASPIS PLP10® INN or Proposed INN: FISH OIL ,RICH IN OMEGA 3 ACIDS Other descriptive name: FISH OIL , RICH IN OMEGA-3-ACIDS INN or Proposed INN: BORAGE OIL 20% GLA Other descriptive name: BORAGE OIL INN or Proposed INN: beta-Carotene Other descriptive name: BETACAROTENE INN or Proposed INN: Gamma-tocopherol	PALUPA Medical Ltd	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	220	Phase 3	Greece
2	NCT02939079 (ClinicalTrials.gov)	April 2015	14/10/2016	Evaluating of the Effect of Fingolimod With Fish Oil on Relapsing-Remitting Multiple Sclerosis Patients	Evaluating the Effect of Fingolimod With Fish Oil Compared to Fingolimod With Placebo on Tumor Necrosis Factor-a , Interleukin1b , Interleukin6, and Interferon-gamma in Patients With Relapsing-Remitting Multiple Sclerosis	Multiple Sclerosis	Drug: Fingolimod;Dietary Supplement: Fish Oil;Drug: Placebo (for Fish Oil)	Isfahan University of Medical Sciences	Shiraz University of Medical Sciences	Completed	18 Years	45 Years	All	50	Phase 2/Phase 3	NULL
3	NCT01842191 (ClinicalTrials.gov)	May 2010	25/4/2013	Efficacy of Fish Oil in Multiple Sclerosis	Efficacy of Fish Oil on Serum TNFa, IL-1ß, IL-6, Oxidative Stress Markers in Multiple Sclerosis Treated With Interferon Beta 1-b	Relapsing- Remitting Multiple Sclerosis	Dietary Supplement: Fish Oil;Dietary Supplement: Placebo	Coordinación de Investigación en Salud, Mexico	NULL	Completed	18 Years	55 Years	Both	50	Phase 4	Mexico
4	NCT00676156 (ClinicalTrials.gov)	December 2005	7/5/2008	A Study of the Pharmacokinetics and Immunologic Effects of Lipoic Acid in Multiple Sclerosis	A Pilot Trial to Study the Pharmacokinetics of Oral Lipoic Acid (LA) and Immunological Effects of LA in Multiple Sclerosis	Multiple Sclerosis	Drug: oral lipoic acid (LA);Drug: lipoic acid (LA) with fish oil and LA without fish oil;Drug: R lipoic acid	Oregon Health and Science University	National Center for Complementary and Integrative Health (NCCIH)	Completed	18 Years	80 Years	Both	40	Phase 1	United States
5	NCT00122954 (ClinicalTrials.gov)	July 2005	20/7/2005	Fish Oil for the Treatment of Depression in Patients With Multiple Sclerosis	Fish Oil as an Adjunct Therapy for Depression in Multiple Sclerosis	Multiple Sclerosis;Depression	Drug: Fish oil concentrate;Drug: Placebo	Oregon Health and Science University	National Center for Complementary and Integrative Health (NCCIH)	Completed	18 Years	85 Years	All	39	Phase 1/Phase 2	United States